<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
For quarterly period ended March 31, 2000 or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
---------- ----------
Commission file number 1-9860
BARR LABORATORIES, INC.
-----------------------
(Exact name of Registrant as specified in its charter)
NEW YORK 22-1927534
-------- ----------
(State or Other Jurisdiction of (I.R.S. - Employer
Incorporation or Organization) Identification No.)
TWO QUAKER ROAD, P. O. BOX 2900, POMONA, NEW YORK 10970-0519
------------------------------------------------------------
(Address of principal executive offices)
914-362-1100
------------
(Registrant's telephone number)
(Former name, former address and former fiscal year, if changed since last
report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No
---
Number of shares of common stock, par value $.01, outstanding as of March 31,
2000: 23,007,468
1
<PAGE> 2
BARR LABORATORIES, INC.
<TABLE>
<CAPTION>
INDEX PAGE
<S> <C>
PART I. FINANCIAL INFORMATION
- --------
Item 1. Financial Statements
Consolidated Balance Sheets as of
March 31, 2000 and June 30, 1999 3
Consolidated Statements of Earnings
for the three and nine months ended
March 31, 2000 and 1999 4
Consolidated Statements of Cash Flows
for the nine months ended
March 31, 2000 and 1999 5
Notes to Consolidated Financial
Statements 6-10
Item 2. Management's Discussion and
Analysis of Financial Condition and
Results of Operations 11-14
Item 3. Quantitative and Qualitative Disclosures
About Market Risk 15
PART II. OTHER INFORMATION
- --------
Item 1. Legal Proceedings 16
Item 6. Exhibits and Reports on Form 8-K 16
SIGNATURES 16
</TABLE>
2
<PAGE> 3
BARR LABORATORIES, INC.
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS OF DOLLARS, EXCEPT SHARE AMOUNTS)
(UNAUDITED)
<TABLE>
<CAPTION>
MARCH 31, JUNE 30,
2000 1999
--------- ---------
<S> <C> <C>
ASSETS
------
Current assets:
Cash and cash equivalents $ 97,446 $ 94,867
Marketable securities 8,111 8,127
Accounts receivable, less allowances of $3,627 and $2,670, respectively 73,446 50,227
Other receivables 23,321 15,750
Inventories 77,682 77,613
Prepaid expenses 1,758 1,556
--------- ---------
Total current assets 281,764 248,140
Property, plant and equipment, net of accumulated depreciation of $50,469
and $45,725, respectively 95,384 93,764
Deferred income taxes 2,445 -
Other assets 9,878 5,986
--------- ---------
Total assets $389,471 $347,890
========= =========
LIABILITIES AND SHAREHOLDERS' EQUITY
------------------------------------
Current liabilities:
Accounts payable $ 80,500 $ 88,982
Accrued liabilities 7,854 9,118
Deferred income taxes 833 833
Current portion of long-term debt 1,924 2,165
Income taxes payable 7,726 179
--------- ---------
Total current liabilities 98,837 101,277
Long-term debt 28,208 30,008
Other liabilities 492 127
Deferred income taxes - 2,771
Commitments & Contingencies
Shareholders' equity:
Preferred stock $1 par value per share; authorized 2,000,000; none issued
Common stock $.01 par value per share; authorized 100,000,000;
issued 23,125,423 and 22,923,583, respectively 231 229
Additional paid-in capital 80,751 76,903
Additional paid-in capital - warrants 16,418 -
Retained earnings 164,400 137,846
Accumulated other comprehensive gain (loss) 147 (1,258)
--------- ---------
261,947 213,720
Treasury stock at cost: 117,955 shares (13) (13)
--------- ---------
Total shareholders' equity 261,934 213,707
--------- ---------
Total liabilities and shareholders' equity $389,471 $347,890
========= =========
</TABLE>
SEE ACCOMPANYING NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS.
3
<PAGE> 4
BARR LABORATORIES, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED NINE MONTHS ENDED
MARCH 31, MARCH 31,
2000 1999 2000 1999
-------- -------- -------- --------
<S> <C> <C> <C> <C>
Revenues:
Product sales $121,522 $115,822 $327,612 $307,608
Development and other revenue 7,238 - 7,238 -
Proceeds from supply agreements 7,000 6,750 20,583 21,333
-------- -------- -------- --------
Total revenues 135,760 122,572 355,433 328,941
Costs and expenses:
Cost of sales 92,889 87,968 236,188 225,796
Selling, general and administrative 10,358 9,129 31,155 28,896
Research and development 9,829 4,835 28,492 15,657
Non-recurring agreement expenses 18,940 - 18,940 -
-------- -------- -------- --------
Earnings from operations 3,744 20,640 40,658 58,592
Interest income 1,107 637 3,276 2,299
Interest expense 603 694 1,892 2,132
Other income 16 1 467 37
-------- -------- -------- --------
Earnings before income taxes 4,264 20,584 42,509 58,796
Income tax expense 1,597 7,922 15,955 22,649
-------- -------- -------- --------
Net earnings $ 2,667 $ 12,662 $ 26,554 $ 36,147
======== ======== ======== ========
Earnings per common share $0.12 $0.56 $1.16 $1.61
======== ======== ======== ========
Earnings per common share - assuming dilution $0.11 $0.54 $1.12 $1.54
======== ======== ======== ========
Weighted average shares 22,979 22,757 22,892 22,434
======== ======== ======== ========
Weighted average shares - assuming dilution 23,866 23,666 23,706 23,496
======== ======== ======== ========
</TABLE>
SEE ACCOMPANYING NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS.
4
<PAGE> 5
BARR LABORATORIES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED MARCH 31, 2000 AND 1999
(IN THOUSANDS OF DOLLARS)
(UNAUDITED)
<TABLE>
<CAPTION>
2000 1999
-------- --------
<S> <C> <C>
CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES:
Net earnings $26,554 $36,147
Adjustments to reconcile net earnings to net cash provided by (used in)
operating activities:
Depreciation and amortization 7,809 6,771
Deferred income tax benefit (6,156) -
Gain on sale of assets (498) -
Fair value of warrants 16,418 -
Other, net 25 18
Changes in assets and liabilities:
(Increase) decrease in:
Accounts receivable and other receivables, net (30,790) (22,630)
Inventories (69) 6,004
Prepaid expenses (202) (933)
Other assets (1,302) (553)
Increase (decrease) in:
Accounts payable, accrued liabilities and other (9,266) (33,965)
Income taxes payable 7,547 (1,982)
-------- --------
Net cash provided by (used in) operating activities 10,070 (11,123)
-------- --------
CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES:
Purchases of property, plant and equipment (9,543) (8,297)
Purchases of strategic investments - (2,250)
Other, net 243 13
-------- --------
Net cash used in investing activities (9,300) (10,534)
-------- --------
CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES:
Principal payments on long-term debt (2,041) (1,833)
Net borrowings under line of credit - (2,500)
Proceeds from exercise of stock options and employee stock purchases 3,850 8,471
-------- --------
Net cash provided by financing activities 1,809 4,138
-------- --------
Increase (decrease) in cash and cash equivalents 2,579 (17,519)
Cash and cash equivalents at beginning of period 94,867 72,956
-------- --------
Cash and cash equivalents at end of period $97,446 $55,437
======== ========
SUPPLEMENTAL CASH FLOW DATA:
Cash paid during the period:
Interest, net of portion capitalized $1,433 $1,676
======== ========
Income taxes $13,719 $20,280
======== ========
Non-cash transactions:
Write-off of equipment & leasehold improvements related to closed factility $115 $83
======== ========
</TABLE>
SEE ACCOMPANYING NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS.
5
<PAGE> 6
BARR LABORATORIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)
1. BASIS OF PRESENTATION
The consolidated financial statements include the accounts of Barr
Laboratories, Inc. and its wholly-owned subsidiaries (the "Company" or
"Barr").
In the opinion of the Management of the Company, the interim consolidated
financial statements include all adjustments, consisting only of normal
recurring adjustments, necessary for a fair presentation of the financial
position, results of operations and cash flows for the interim periods.
Interim results are not necessarily indicative of the results that may be
expected for a full year. These financial statements should be read in
conjunction with the Company's Annual Report on Form 10-K for the year
ended June 30, 1999 and quarterly reports on Form 10-Q for the periods
ended September 30, 1999 and December 31, 1999.
2. CASH AND CASH EQUIVALENTS
Cash equivalents consist of short-term, highly liquid investments
(primarily market auction securities with interest rates that are re-set
in intervals of 7 to 28 days) which are readily convertible into cash at
par value (cost).
As of March 31, 2000 and June 30, 1999, approximately $45,363 and
$28,283, respectively, of the Company's cash was held in an interest
bearing escrow account. Such amounts represent the portion of the
Company's payable balance with the Innovator of Tamoxifen which the
Company has decided to secure in connection with its cash management
policy. The Company pays the Innovator a monthly fee based on a rate
multiplied by the average unsecured monthly Tamoxifen payable balance.
3. OTHER RECEIVABLES
Other receivables consist of $16,083 in supply agreement receivables and
$7,238 in receivables related to development and other revenues (See Note
5 to the Consolidated Financial Statements).
6
<PAGE> 7
4. INVENTORIES
Inventories consisted of the following:
<TABLE>
<CAPTION>
March 31, June 30,
2000 1999
------------------- ------------------
<S> <C> <C>
Raw materials and supplies $ 13,467 $ 15,790
Work-in-process 6,640 7,957
Finished goods 57,575 53,866
------------------- ------------------
$77,682 $ 77,613
=================== ==================
</TABLE>
Tamoxifen Citrate, purchased as a finished product, accounted for
approximately $44,816 and $43,040 of finished goods as of March 31, 2000
and June 30, 1999, respectively.
5. DUPONT PHARMACEUTICALS COMPANY STRATEGIC ALLIANCE
On March 20, 2000, the Company signed definitive agreements to establish
a strategic relationship with DuPont Pharmaceuticals Company ("DuPont")
to develop, market and promote several proprietary products and to
terminate all litigation between the two companies.
Development and Other Revenue
In connection with a proprietary product development funding agreement
("Product Development Agreement"), DuPont may invest up to $45 million
over three years to support the development of three of the Company's
proprietary products. All amounts received under the Product Development
Agreement will be recorded as Development and other revenue. Upon
approval of the products, Barr will be responsible for marketing the
products and DuPont will receive royalties based on product sales. In
connection with the Product Development Agreement, the Company recorded
$4 million as Development and other revenue for the three months ended
March 31, 2000.
In a second agreement, DuPont will assume responsibility for sales and
marketing support of an undisclosed proprietary product that Barr expects
to launch in the first calendar quarter of 2001 ("Development and
Marketing Agreement"). In connection with the Development and Marketing
Agreement, DuPont may make milestone payments of up to $9 million over
five quarters. In the three months ended March 31, 2000 the Company
recorded $2 million as Development and other revenue related to this
agreement.
Under the terms of a third agreement, Barr has agreed to be the sole
distributor in the United States and Canada of DuPont's Viaspan(R) organ
transplant preservation agent ("Viaspan Agreement"). During a transition
period, not expected to continue past November 30, 2000, DuPont will
remain the distributor of Viaspan and will pay a fee to Barr based on a
defined formula ("Transition Revenue"). Such Transition Revenue will be
included in Development and other revenue until Barr assumes
responsibility for distributing the product. Once Barr assumes
responsibility for distributing the product, the Company will record
product sales and related costs on the respective lines of its
Consolidated Statements of Earnings. For the three months ended March 31,
2000, the Company recorded approximately $1.2 million as Development and
other revenue related to the Viaspan Agreement.
7
<PAGE> 8
Warrants
In connection with the above agreements, the Company issued two warrants
granting DuPont the right to purchase 500 shares of Barr's common stock
at $47 per share and 500 shares at $57 per share, respectively. Each
warrant is immediately exercisable and has a four-year term. In
connection with the issuance of such warrants, the Company recorded a
one-time, non-cash charge of approximately $16.4 million. This amount is
recorded as part of the Non-recurring agreement expenses on the
Consolidated Statements of Earnings for the three months ended March 31,
2000. The charge was calculated using a Black-Scholes option pricing
model with the following assumptions: dividend yield 0%, volatility 38%,
risk-free interest rate 7.13% and a life of 4 years.
6. NON-RECURRING AGREEMENT EXPENSES
Non-recurring agreement expenses include a non-cash charge associated
with the issuance of one million warrants (See Note 5 to the Consolidated
Financial Statements) and approximately $2,500 in one-time legal charges,
primarily related to a special fee paid to the Company's outside legal
counsel, associated with finalizing the definitive agreements with
DuPont.
7. EARNINGS PER SHARE
The following is a reconciliation of the numerators and denominators used
to calculate Earnings per common share on the Consolidated Statements of
Earnings:
<TABLE>
<CAPTION>
THREE MONTHS ENDED NINE MONTHS ENDED
MARCH 31, MARCH 31,
2000 1999 2000 1999
------- ------- ------- -------
<S> <C> <C> <C> <C>
EARNINGS PER COMMON SHARE:
Net earnings (numerator) $ 2,667 $12,662 $26,554 $36,147
Weighted average shares (denominator) 22,979 22,757 22,892 22,434
Net earnings $ 0.12 $ 0.56 $ 1.16 $ 1.61
======= ======= ======= =======
EARNINGS PER COMMON SHARE - ASSUMING DILUTION:
Net earnings (numerator) $ 2,667 $12,662 $26,554 $36,147
Weighted average shares 22,979 22,757 22,892 22,434
Effect of dilutive options 887 909 814 1,062
------- ------- ------- -------
Weighted average shares - assuming
dilution (denominator) 23,866 23,666 23,706 23,496
Net earnings $ 0.11 $ 0.54 $ 1.12 $ 1.54
======= ======= ======= =======
</TABLE>
During the three and nine months ended March 31, 2000 and 1999, there
were 1,040, 1,040, 225 and 514, respectively, of outstanding options and
warrants that were not included in the
8
<PAGE> 9
computation of diluted EPS, because the securities' exercise prices were
greater than the average market price of the common stock for the period.
8. COMPREHENSIVE INCOME
Comprehensive income is defined as the total change in shareholders'
equity during the period other than from transactions with shareholders.
For the Company, comprehensive income is comprised of net income and the
net changes in unrealized gains and losses on securities classified for
Statement of Financial Accounting Standards ("SFAS") No. 115 purposes as
"available for sale". Total comprehensive income for the three and nine
months ended March 31, 2000 and 1999 was $3,807, $27,959, $12,690 and
$35,693, respectively.
9. NEW ACCOUNTING PRONOUNCEMENT
On June 15, 1998, the Financial Accounting Standards Board ("FASB")
issued SFAS No. 133, "Accounting for Derivative Instruments and Hedging
Activities," which requires that companies recognize all derivatives as
either assets or liabilities on the balance sheet and measure those
instruments at fair value. In June 1999, the FASB issued SFAS No. 137,
"Accounting for Derivative Instruments and Hedging Activities - Deferral
of the Effective Date of FASB Statement No. 133," which defers the
effective date of SFAS No. 133 until the Company's fiscal year 2001. The
Company is currently evaluating this statement and its impact on the
Company's existing accounting policies and financial reporting
disclosures.
10. STRATEGIC COLLABORATIONS
The Company, from time to time, enters into development or supply
collaborations or makes investments in third parties to support the
Company's business strategies. These collaborations include, but are not
limited to, agreements with suppliers for raw materials, licensing
technologies for generic or proprietary products and making equity or
debt investments in third parties. Financial terms may include cash
payments upon execution of an agreement or upon achieving certain
milestones or upon successful launch and commercialization of the
developed product. Such payments are either capitalized as other assets
and amortized or expensed as research and development, depending upon the
nature of the payment. Many of these arrangements include termination
provisions that allow the Company to withdraw from a project if it is
deemed no longer appropriate by the Company.
11. COMMITMENTS AND CONTINGENCIES
Invamed, Inc./Apothecon, Inc. Lawsuit
In February 1998 and May 1999, Invamed, Inc. ("Invamed") and Apothecon,
Inc. ("Apothecon"), respectively, named the Company and several others as
defendants in a lawsuit filed in the United States District Court for the
Southern District of New York, charging that the Company unlawfully
blocked access to the raw material source for Warfarin Sodium. The
Company believes that the suit is without merit and intends to defend its
position vigorously. These actions are currently in discovery stage. It
is anticipated that this matter will take a significant period of time to
be resolved but an adverse judgement could have a material impact on the
Company's consolidated financial statements.
9
<PAGE> 10
Other Litigation
As of March 31, 2000, the Company was involved in other lawsuits
incidental to its business, including patent infringement actions.
Management of the Company, based on the advice of legal counsel, believes
that the ultimate disposition of such other lawsuits will not have any
significant adverse effect on the Company's consolidated financial
statements.
Administrative Matters
Federal antitrust authorities have undertaken a review of certain trade
practices within the pharmaceutical industry, specifically patent
challenge settlements, unfair trade practices by brand drug companies and
exclusive supply arrangements. The Company has voluntarily discussed with
the Federal Trade Commission ("FTC") its arrangements with the supplier
of the raw material for its Warfarin Sodium. The Company has voluntarily
responded to requests from the Department of Justice by providing
documents relating to the settlement of its Tamoxifen patent challenge.
On June 30, 1999, the Company received a subpoena and civil investigative
demand from the FTC relating to its March 1997 patent litigation
settlement regarding ciprofloxacin hydrochloride. The Company complied
with the terms of the requests and since then has not received any
further requests. The Company believes that it has complied with all
applicable laws and regulations governing trade and competition in the
marketplace in connection with its arrangements with its raw material
suppliers and its two patent challenge settlements.
10
<PAGE> 11
ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
Results of Operations:
Comparison of the Three Months Ended March 31, 2000
to the Three Months Ended March 31, 1999 - (thousands of dollars)
Total revenues increased approximately 11% as a result of increased Product
sales and Development and other revenue.
Tamoxifen sales increased 9% from $83,929 to $91,361. The increase was due to
higher prices and an expansion in the use of Tamoxifen. In October 1998,
Tamoxifen was approved to reduce the incidence of breast cancer in women at high
risk of developing the disease. Tamoxifen is a patent protected product
manufactured for the Company by the Innovator. Currently, Tamoxifen only
competes against the Innovator's product, which is sold under the brand name.
The prior year sales included $2,345 of Minocycline sales which the Company
stopped selling in late 1999 because of deteriorating market conditions.
Other product sales increased 2% from $29,548 to $30,161. The increase was lead
by higher sales of Medroxyprogesterone, Naltrexone, Hydroxyurea, Warfarin and
sales of Cefadroxil, which the Company launched in June 1999. These increases
were driven mainly by increases in market share, which more than offset price
declines and higher discounts on certain of the Company's products.
Development and other revenue consists of amounts received from DuPont
Pharmaceuticals Company ("DuPont") for various development and co-marketing
agreements including $1.2 million in Transition Revenue associated with the
Viaspan Agreement (See Note 5 to the Consolidated Financial Statements). Once
the Company begins distributing Viaspan it will record such sales as part of
Product sales and Cost of sales.
Cost of sales increased to $92,889 or 76.4% of product sales from $87,968 or
76.0% of product sales. The increase in both dollars and percent of product
sales was due to increased product sales, an increased percentage of Tamoxifen
sales to total product sales and a less favorable mix within other products.
Tamoxifen is distributed by the Company and has lower margins than most of
Barr's other products.
Selling, general and administrative expenses increased from $9,129 to $10,358.
The increase was primarily due to an increase in legal spending related to
patent challenge activities. Also, the prior year included approximately $1.7
million received from Eli Lilly & Company for reimbursement of legal costs.
Total research and development expenses in the quarter increased from $4,835 to
$9,829. This increase resulted from increased bio-study and clinical trial costs
and higher personnel costs, each supporting an increased number of products in
development. Also, the prior year included $646 related to a proprietary product
collaboration with Eastern Virginia Medical School.
Non-recurring agreement expenses consists of a one-time non-cash charge
representing the fair value of the one million warrants issued to DuPont (See
Note 5 to the Consolidated Financial Statements) as well as approximately $2,500
in one-time legal charges associated with finalizing the Company's definitive
agreements with DuPont.
11
<PAGE> 12
Interest income increased by $470 primarily due to an increase in the average
cash and cash equivalents balance, as well as an increase in the market rates on
the Company's short-term investments.
Interest expense decreased $91 primarily due to lower fees paid on the average
unsecured Tamoxifen payable balance.
Results of Operations:
Comparison of the Nine Months Ended March 31, 2000
to the Nine Months Ended March 31, 1999 - (thousands of dollars)
Total revenues increased approximately 8% as a result of increased Product sales
and Development and other revenue partially offset by a decrease in Proceeds
from supply agreements.
Tamoxifen sales increased 9% from $203,302 to $221,832. The increase is
attributable to higher prices and an expansion in the use of Tamoxifen.
The prior year sales included $6,373 of Minocycline sales which the Company
stopped selling in late 1999 because of deteriorating market conditions.
Other product sales increased 8% from $97,933 to $105,648. The increase was led
by higher sales of Medroxyprogesterone, Naltrexone, Hydroxyurea, Cefadroxil and
Danazol. These increases were driven mainly by increases in market share which
more than offset price declines on certain of the Company's other products.
Development and other revenue consists of amounts received from DuPont for
various development and co-marketing agreements including $1.2 million in
Transition Revenue associated with the Viaspan Agreement (See Note 5 to the
Consolidated Financial Statements). Once the Company begins distributing Viaspan
it will record such sales as part of Product sales and Cost of Sales.
Proceeds from supply agreements declined $750, as expected, since proceeds
earned in the prior year under a separate contingent supply agreement related to
the ciprofloxacin litigation ceased.
Cost of sales increased from $225,796 to $236,188 primarily related to an
increase in product sales. As a percentage of product sales, cost of sales
declined from 73.4% to 72.1%. This percentage decline was attributable to a more
favorable mix within other products, offset slightly by an increased percentage
of sales of Tamoxifen to total sales. Tamoxifen is distributed by the Company
and has lower margins than most of Barr's other products.
Selling, general and administrative expenses increased from $28,896 to $31,155.
The increase was primarily due to increased legal costs, partially offset by a
decrease in advertising and promotions. The increase in legal fees was primarily
due to an increase in patent challenge activities. Also, the prior year included
approximately $1.7 million received from Eli Lilly & Company for reimbursement
of legal costs. Advertising and promotional costs declined, primarily as a
result of less media advertising.
Total research and development expenses increased from $15,657 to $28,492. This
increase results from increased bio-study and clinical trial costs and higher
personnel costs, each supporting an increased number of products in development.
Also, the prior year included $646 related to a proprietary product
collaboration with Eastern Virginia Medical School.
12
<PAGE> 13
Non-recurring agreement expenses consist of a one-time non-cash charge
representing the fair value of the one million warrants issued to DuPont (See
Note 5 to the Consolidated Financial Statements) as well as approximately $2,500
in one-time legal charges associated with finalizing the Company's definitive
agreements with DuPont.
Interest income increased by $977 primarily due to an increase in the average
cash and cash equivalents balance, partially offset by a decrease in the market
rates on the Company's short-term investments. The decrease in the market rates
was primarily the result of the Company investing in a greater amount of
tax-free investments which generally have lower rates than taxable investments,
but reduce the effective tax rate of the Company.
Interest expense decreased $240 due to a decrease in the Company's debt balances
and lower fees paid on the average unsecured Tamoxifen payable balance.
Other income increased $430 primarily due to the gain recognized on the warrants
received from Halsey Drug Co., Inc.
Liquidity and Capital Resources
The Company's cash and cash equivalents increased from $94,867 at June 30, 1999
to $97,446 at March 31, 2000. During the nine months ended March 31, 2000, the
Company increased the cash held in its interest bearing escrow account from
$28,283 at June 30, 1999 to $45,363.
Cash provided by operating activities totaled $10,070 for the nine months ended
March 31, 2000 as net earnings and non-cash charges such as fair value of
warrants, depreciation and deferred income tax benefit more than offset working
capital increases. Working capital increases were led by increases in accounts
receivable and other receivables and a decrease in accounts payable, which were
partially offset by an increase in income taxes payable. Accounts receivable at
March 31, 2000 were $73,446 or $23,219 higher than those at June 30, 1999. This
increase was primarily attributable to increased product sales. Other
receivables increased due to Development and other revenue (See Note 5 to the
Consolidated Financial Statements). The decrease in accounts payable related to
the pay down of the Tamoxifen payable. Income taxes payable increased due to the
timing of estimated tax payments.
During the first nine months of fiscal 2000, the Company invested approximately
$9.5 million in capital expenditures primarily related to the construction of
its new 48,000 square foot warehouse and 13,500 square foot laboratory facility
at its Pomona, New York campus. The Company expects to invest an additional $2
million in capital assets in the fourth quarter of fiscal 2000.
To expand its growth opportunities, the Company has and will continue to
evaluate and enter into various strategic collaborations (See Note 10 to the
Consolidated Financial Statements). The timing and amount of cash required to
enter into these collaborations is difficult to predict because it is dependent
on several factors, many of which are outside of the Company's control. However,
the Company believes, that based on arrangements in place at March 31, 2000, it
could spend between $2 and $4 million over the next twelve months for these
collaborations. The $2 to $4 million excludes any cash needed to fund strategic
acquisitions the Company may consider in the future.
The Company believes that its current cash balances, cash flows from operations
and borrowing capacity, including unused amounts under its existing Revolving
Credit Facility, will be adequate to meet its needs and to take advantage of
strategic opportunities as they occur. To the extent that
13
<PAGE> 14
additional capital resources are required, such capital may be raised by
additional bank borrowings, equity offerings or other means.
Outlook
The Company's product sales are dependent upon several factors including the
timing of new product launches, increases or decrease in market share, changes
in prices and customer buying patterns. As a result, forecasting product sales
from period to period is difficult. However, total Product sales are expected to
be lower in the fourth quarter due to an anticipated reduction in Tamoxifen
sales. Historically, Tamoxifen sales have fluctuated significantly among the
Company's fiscal quarters. These fluctuations may be based on several factors
including the buying patterns of several large customers. These buying patterns
have been influenced by those buyers attempting to anticipate the timing of
Tamoxifen price increases. Tamoxifen's last price increase occurred in May 1999.
However, because Barr distributes Tamoxifen, the timing and extent of price
increases are unknown and determined solely by the Innovator. Non-Tamoxifen
product sales are expected to increase in the fourth quarter offsetting some of
the Tamoxifen sales decline.
The Company's profit margins on product sales are impacted by numerous factors
such as product pricing, product sales mix, including the percentage of
Tamoxifen sales to total product sales, and manufacturing efficiencies. Overall
margins declined in the third quarter as expected primarily due to an increasing
percentage of total sales being accounted for by Tamoxifen. Based on anticipated
sales trends described above, Tamoxifen sales are expected to make up a smaller
percentage of total sales in the fourth quarter and therefore overall margins
are expected to increase.
Revenues earned under the various DuPont agreements are determined by several
factors including the timing and extent of Barr's spending on specific
proprietary development products, and achieving certain development milestones.
Therefore, forecasting such revenues is difficult. In the fourth quarter, Barr
expects to earn an amount within 5% to 10% of the amount earned in the third
quarter.
In September, the Company publicly disclosed that it expected its investment in
research and development to be between $40-$45 million. Based on actual spending
through the third quarter of approximately $28.5 million, the Company believes
total spending for the year will approach the low end of that range.
In the fourth quarter, Selling, general and administrative expenses are expected
to be consistent with the third quarter.
Forward-Looking Statements
Except for the historical information contained herein, this Form 10-Q contains
forward-looking statements, all of which are subject to risks and uncertainties.
Such risks and uncertainties include the timing and outcome of legal
proceedings, impact of competition on sales and profitability of key products,
the timing or occurrence of price increases on key products, the timing of FDA
approvals and product launches, capital spending, the ability of the Company to
obtain additional capital and other risks detailed from time-to-time in the
Company's filings with the Securities and Exchange Commission. Forward-looking
statements can be identified by their use of words such as "expects," "plans,"
"will," "believes," "may," "estimates," "intends" and other words of similar
meaning. Should known or unknown risks or uncertainties materialize, or should
our assumptions prove inaccurate, actual results could vary materially from
those anticipated. The Company undertakes no obligation to publicly update any
forward-looking statements.
14
<PAGE> 15
ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As discussed in the 1999 Annual Report on Form 10-K, the Company's exposure to
market risk from changes in interest rates, in general, is not material.
15
<PAGE> 16
BARR LABORATORIES, INC.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
DuPont Anti-Trust Suit
As disclosed in the Company's Annual Report on Form 10-K, on
March 9, 1998, the Company filed an anti-trust suit against
DuPont Merck Pharmaceutical Company ("DuPont") in the United
States District Court for the Southern District of New York,
charging that DuPont had acted unlawfully to impede the
marketplace acceptance of Barr's generic version of the
anti-coagulant Coumadin. The Company agreed to a dismissal
with prejudice on March 20, 2000.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibit Number Exhibit
-------------- -------
27.0 Financial data schedule
10.15 Proprietary Drug Development and
Marketing Agreement, dated March
20, 2000 (portions of this exhibit
have been omitted pursuant to a
request for confidential treatment)
(b) The following report was filed by the Company on Form 8-K in
the quarter ended March 31, 2000:
Report Date Item Reported
----------- -------------
January 21, 2000 Company announced the signing of a
letter of intent to establish a
strategic relationship with DuPont
Pharmaceuticals Company
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
BARR LABORATORIES, INC.
Dated: May 1, 2000 /s/ William T. McKee
--------------------
William T. McKee
Chief Financial Officer
16
<PAGE> 1
EXHIBIT 10.15
The Company has filed with the Commission a written objection to the public
disclosure of certain information contained in this document. The Company has
omitted material from this document at the places marked with three asterisks
(***), both at the beginning and the end of the material. The omitted material
has been filed separately with the Commission.
-0-
<PAGE> 2
PROPRIETARY DRUG DEVELOPMENT AND MARKETING AGREEMENT
This PROPRIETARY DRUG DEVELOPMENT AND MARKETING AGREEMENT
("Agreement"), effective on March 20, 2000 (the "Effective Date"), is made by
and between Barr Laboratories, Inc., a corporation organized and existing under
the laws of New York and having its principal offices at 2 Quaker Road, Pomona,
New York 10970 (hereinafter "Barr"), and DuPont Pharmaceuticals Company
(hereinafter "DuPont"), a general partnership organized and existing under the
laws of the State of Delaware and having its principal offices at Chestnut Run
Plaza, 974 Centre Road, Wilmington, Delaware 19807-2802.
WHEREAS, DuPont is in the business of discovering, developing,
manufacturing and marketing new chemical entities as pharmaceutical products;
WHEREAS, Barr is in the business of developing, manufacturing and
marketing generic and proprietary drugs, and in particular is developing
CyPat(TM), Seasonale(TM) and *** as proprietary drugs;
WHEREAS, the Parties have determined that certain proprietary drugs
under development at Barr may be more efficiently and effectively developed and
marketed through a beneficial collaboration, and in particular, that
collaborative development and marketing of CyPat(TM), Seasonale(TM) and ***
would be beneficial to the Parties and their patients;
WHEREAS, DuPont is not in the position to develop CyPat(TM),
Seasonale(TM) and *** itself and believes that collaborative development
CyPat(TM), Seasonale(TM) and *** would be beneficial to the Parties; and
WHEREAS, the Parties wish to create an alliance that permits such
efficient and effective development and marketing.
NOW, THEREFORE, in consideration of the mutual promises hereinafter set
forth, and intending to be legally bound hereby, Barr and DuPont hereby agree as
follows:
1. Definitions.
Each of the capitalized terms used in this Agreement (other than the
headings of the Sections) shall have the meaning indicated in this Agreement.
1.1 The term "Affiliate" or "Affiliated" shall mean, with respect
to a Party, any other business entity which directly or indirectly controls, is
controlled by, or is under common control with, such Party. As used in this
definition of "Affiliate," the term "control" shall mean direct or indirect
beneficial ownership of more than fifty percent (50%) of the voting or income
interest in such business entity.
-1-
<PAGE> 3
1.2 The term "Affiliated Customer" shall mean, with respect to a
Party, any Affiliate.
1.3 The term "Agency" as used herein means any governmental
regulatory authority responsible for granting health or pricing approvals,
registrations, import permits, and other approvals required before a Funded
Product may be tested or marketed in any country. The term Agency includes the
Food and Drug Administration ("FDA").
1.4 The term "Agency Approval" shall mean final authorization by
an Agency to market and sell the Funded Products in a country in the Territory.
1.5 The term "Commercially Reasonable Efforts" as used herein
shall mean those efforts consistent with the exercise of prudent scientific and
business judgment as applied to other research, development and
commercialization efforts for products of similar scientific and commercial
potential within the research programs and relevant product lines of such Party.
1.6 The term "CyPat(TM)" as used herein means cyproterone acetate,
a synthetic oral hydroxyprogesterone agent used in the treatment of prostate
cancer and its associated syndromes.
1.7 The term "Development Costs" as used herein means External
Verifiable Development Expense and Internal Verifiable Development Expense.
1.8 The term "***" as used herein means ***
***.
1.9 The term "External Verifiable Development Expense" as used
herein includes those external costs to acquire, develop and submit the Funded
Products to the FDA for approval and reported as research and development
expense on financial statements to shareholders and consistent with Financial
Accounting Statement No. 2. Such costs include, but are not limited to, the
expenses included in Attachment A hereto.
1.10 The term "First Commercial Sale" shall mean, with respect to
the Funded Products, the first sale for use or consumption by the public of such
Funded Products in the Territory after all required approvals, including
marketing approval, have been granted by the FDA.
1.11 The term "Funded Products" as used herein means Barr's
proprietary development candidates CyPat(TM), Seasonale(TM), *** and any
proprietary drug substituted pursuant to Section 2.9 hereof. The term "Funded
Product" refers to any one of the preceding development candidates in the
singular.
1.12 The term "Internal Verifiable Development Expenses" as used
herein means those internal costs to develop and submit the Funded Products to
the FDA for approval and reported as research and development expense on
financial statements to shareholders and consistent with
-2-
<PAGE> 4
Financial Accounting Statement No. 2. Such costs include, but are not limited
to, the expenses included in Attachment A hereto.
1.13 The term "Net Sales" shall mean the aggregate gross invoice
price of Funded Products sold by Barr and its Affiliates and its licensees, to
an independent Third Party in bona-fide, arms-length transactions, in the
Territory after deducting (to the extent actually incurred and to the extent not
already deducted in the amount invoiced): (i) customary trade, cash and quantity
discounts, (ii) rebates, adjustments and allowances, including for rejections,
recall, returns, and floorstock adjustments, (iii) Medicaid and other federal or
state rebates, chargebacks and similar items, (iv) if included in the aggregate
gross invoice price of Product, custom duties, sales or excise taxes (including
any such tax as a value added tax or similar tax or charge), and (v) if included
in the aggregate gross invoice price of Product, freight and insurance on
shipment of Product.
1.14 The term "Non-Affiliated Customer" shall mean any purchaser of
a Funded Product who is not an Affiliated Customer.
1.15 The term "Party" means Barr or DuPont and, when used in the
plural, shall mean Barr and DuPont.
1.16 The term "Patent Right" as used herein shall mean (a) all
patent applications heretofore or hereafter filed in any country owned or
controlled or licensed to Barr during the term of this Agreement, together with
any and all United States and foreign patents that have issued or in the future
will issue therefrom, and (b) all divisionals, continuations,
continuations-in-part, reexaminations, reissues, renewals, substitutions,
confirmation, registrations, revalidations, extensions or additions to any such
patents and patent applications and patents issuing thereon; all to the extent
and only to the extent that Barr now has or hereafter will have the right to
grant licenses or other rights thereunder.
1.17 The term "Research Management Committee" or "RMC" as used
herein shall mean the committee described in Section 2.1 hereof.
1.18 The term "Research Program" as used herein means any and all
research, development and manufacturing activities necessary or appropriate to
gain Agency approval for the Funded Products. The Research Program and the
timeline therefor shall be more fully described in a separate document to be
delivered by Barr no later than May 1, 2000.
1.19 The term "Sales Year" shall mean (i) with respect to the first
Sales Year, the period commencing on the Effective Date and ending on June 30,
2000; (ii) with respect to the second through tenth Sales Years (2001 - 2009),
each such fiscal year.
1.20 The term "Seasonale(TM)" as used herein means Barr's agent
combining levonorgestrel and ethinyl estradiol.
-3-
<PAGE> 5
1.21 The term "Territory" as used herein means the entire world.
1.22 The term "Third Party" shall mean any party other than Barr or
DuPont or an Affiliate of either of them.
2. Development and Commercialization.
2.1 A Research Management Committee (the "RMC") will be
established which will be responsible for the management of the Research
Program. The RMC will prepare and review the annual research plans, monitor the
progress of Barr in performing the Research Program and determine whether the
research milestones as set forth therein have been successfully completed. The
RMC will be comprised of five (5) members with three (3) representatives
appointed by Barr and two (2) representatives appointed by DuPont. The RMC shall
be co-chaired jointly by the Project Leaders as defined in Section 2.4 below.
Either Party, in its sole discretion, may appoint substitute or replacement
members of the RMC to serve as its representatives upon notice to the other
Party. The initial members of the RMC shall be appointed by the Parties within
thirty (30) days following the Effective Date.
2.2 The RMC shall meet at least once each quarter or such lesser
frequency as the Parties shall determine during the term of the Research
Program, at such times and places as agreed to by Barr and DuPont, alternating
between Pomona, New York and Wilmington, Delaware, or such other locations as
the Parties shall agree. The Party hosting each meeting of the RMC promptly
shall prepare and deliver to the other Party within fifteen (15) business days
after the date of such meeting, minutes of such meeting setting forth all
decisions of the RMC relating to the Research Program in form and content
reasonably acceptable to the other Party. The RMC and any of its members may
meet or attend meetings by telephone or video conference. The RMC will
communicate regularly by telephone, facsimile and video conference. Meetings and
telephone and video conferences of the RMC may be attended by such other
directors, officers, employees, consultants and other agents of Barr and DuPont
as the Parties from time to time reasonably agree.
2.3 All decisions of the RMC shall be made by majority vote of all
of the members, with each member of the RMC entitled to one vote.
2.4. Barr and DuPont each shall appoint a person (a "Project
Leader") to coordinate its part of the Research Program. The Project Leaders
shall be the primary contacts between the Parties with respect to the Research
Program. Each Party shall notify the other within thirty (30) days of the
Effective Date of the appointment of its Project Leader and shall promptly
notify the other Party upon changing this appointment.
2.5 By May 1, 2000, Barr will provide DuPont with a written
description of the Research Program, such description having sufficient detail
so as to enable DuPont to understand the goals and objectives of the Research
Program. At the end of each quarter thereafter, Barr will provide DuPont with
written reports of progress made towards achieving the goals of the
-4-
<PAGE> 6
Research Program and the path Barr expects to follow in the next quarter, such
reports having sufficient detail so as to enable DuPont to ascertain Barr's
progress and Barr's direction towards fulfilling the goals and objectives of the
Research Program. Barr shall have sole discretion to direct and control the
Research Program and shall use Commercially Reasonable Efforts to carry out all
activities under the Research Program at its own expense, and to complete it
within the timelines approved by the RMC, provided that neither the Research
Program nor anything in this Agreement shall constitute any warranty or covenant
that the Funded Products will be successfully developed at all or over such
timeline. Barr shall at the soonest practicable time (in its sole discretion),
consistent with sound scientific and business principles, file applications for
Agency approval to sell Funded Products in the United States and other countries
where there is a reasonable market opportunity and shall thereafter maintain in
full force and effect Agency Approval for the Funded Products in such
jurisdictions where it deems it appropriate (in its sole discretion). Barr shall
be the sole owner of all such applications and/or approvals related to the
Funded Products.
2.6 Barr shall be the sole owner of any and all Patent Rights,
data, information, inventions and discoveries generated as a result of the
Research Program. As owner, Barr shall have the right, at its option and expense
and through attorneys and agents of its choice, to prepare, file and prosecute
(including any proceedings relating to reissues, reexaminations, protests,
interferences and requests for patent extensions or supplementary protection
certificates) in its own name any patent applications with respect to any of the
above owned by it and to maintain any patents issued. In connection therewith,
DuPont agrees to cooperate with Barr at Barr's expense in the preparation and
prosecution of all such patent applications and in the maintenance of any
patents issued. The obligations set forth in this Section 2.6 shall survive the
expiration or termination of this Agreement.
2.7 In the event that DuPont becomes aware of any actual or
threatened infringement of any Patent Right of Barr, DuPont shall promptly
notify Barr, and Barr shall control alone the conduct of any legal action or
proceeding, and shall bear the actual costs and expenses of such action.
2.8 Barr shall use good faith, Commercially Reasonable Efforts, to
commercialize each Funded Product, after gaining Agency Approval and to market
and sell them after gaining Agency Approval, in each case consistent with the
usual methods followed by Barr in commercializing, marketing and selling its
other pharmaceutical products. DuPont acknowledges that Barr shall have the sole
responsibility for the manufacture, packaging, distribution, marketing, pricing,
supply, shipping, warehousing, invoicing, billing and for collection of
receivables resulting from sales of the Funded Products. At all times during the
Research Program, Barr shall undertake all Commercially Reasonable Efforts to
make available and sell sufficient quantities of the Funded Products to meet the
requirements of its customers, taking into account the actual demand for the
Funded Products and the marketing strategy for each Funded Product. DuPont
recognizes and accepts that the final decision for the allocation of the Funded
Products in the event of a shortage rests with Barr. Barr may take into
consideration
-5-
<PAGE> 7
the global market Barr is obligated to supply in determining such allocation.
DuPont also recognizes and accepts that the final decision for the pricing of
the Funded Products rests with Barr.
2.9 As a one-time opportunity, Barr may substitute one other
proprietary drug development product for any of the three Funded Products in the
first eighteen (18) months following the Effective Date; provided that DuPont
agrees to such substitution, which agreement shall not be unreasonably withheld.
In such event, the substitute proprietary drug shall be considered a Funded
Product and shall be subject to all terms and conditions relating to Funded
Products.
3. Right of First Offer.
Barr hereby grants DuPont and DuPont hereby accepts a right of first
offer to be Barr's sales and marketing partner should Barr desire to have a
sales and marketing partner in any country of the Territory for any of the
Funded Products. At such time that Barr decides it would like to seek such a
sales and marketing partner, Barr will provide DuPont all information necessary
for DuPont to make an informed decision about its level of interest. DuPont will
then have thirty (30) business days from receipt of all such information to make
a first offer to Barr for such country and such Funded Product. In the event
that Barr accepts DuPont's offer, then the Parties will promptly negotiate and
execute a definitive agreement within thirty (30) business days covering agreed
upon terms and conditions of the sales and marketing partnership. In the event
Barr declines DuPont's offer, then Barr will so notify DuPont. If Barr does not
accept DuPont's offer, then Barr may offer the opportunity to market and sell
the Funded Product to a Third Party, provided that Barr shall not accept from a
Third Party an offer unless such other offer shall, be more economically
favorable to Barr. The Parties acknowledge and agree that the determination of a
more economically favorable offer may include factors in addition to the
financial terms of an offer. Nothing in this Agreement shall prohibit Barr from
selling and marketing Funded Products in the Territory without offering the
rights set forth in this Section 3 to DuPont.
4. Development Financing.
4.1 DuPont will make available to Barr up to forty-five million
United States Dollars (45,000,000 USD) in research and development funding for
the Research Program. ***
***. The total funding to be provided by DuPont for all three
Funded Products shall be limited to Development Costs and shall be limited by
calendar quarter as set forth in Exhibit I. If development of a Funded Product
is discontinued, no additional funding for that Funded Product will be made
after the date of discontinuance, and funding for the other Funded Products will
not be increased beyond the levels provided for under Section 4.1 for each
Funded Product. Substitution of another drug development product, as allowed in
Section 2.9 hereinabove, shall not increase the amount of funding provided under
this Section
-6-
<PAGE> 8
4.1. The substitute program will be funded only with those amounts
remaining from the fund of the substituted Funded Product. None of Barr's costs
or expenses with respect to *** shall be charged as Development Costs, unless
Barr obtains rights to ***.
4.2 Within sixty (60) of the end of the first calendar quarter and
thirty (30) days of the end of each calendar quarter thereafter, Barr will
provide DuPont with a report that details by Funded Product the composition and
elements included in determining the Development Costs for that quarter. Within
thirty (30) days of receiving said report, DuPont will pay Barr, the lower of
the Development Costs for that quarter or the amount specified in Exhibit I.
4.3 Barr will provide DuPont thirty (30) days prior to the end of
each calendar quarter, a good faith estimate of Development Costs for such
current quarter. Such estimate shall be for accounting purposes and shall not be
binding.
4.4 All payments to be made under this Agreement shall be made in
United States dollars in the United States by wire transfer to a bank account
designated by the Party to be paid. In the event that any payment due under this
Agreement is not made when due, the payment shall accrue interest from the date
due at the rate of eighteen percent (18%) per annum; provided, that in no event
shall such rate exceed the maximum legal annual interest rate. The payment of
such interest shall not limit a Party from exercising any other rights it may
have as a consequence of the lateness of any payment.
4.5 As a one-time occurrence, Barr will be allowed to include in
the amounts provided under Section 4.1 hereinabove its External Verifiable
Development Expenses for the Funded Products during the calendar quarter ending
December 31, 1999. If Barr acquires rights to develop ***, Barr also will be
allowed to include in the amounts provided under Section 4.1 hereinabove its
External Verifiable Development Expenses for *** beginning October 1, 1999. All
of such costs for the calendar quarter ending December 31, 1999 shall not ***
*** and shall be counted as an
External Verifiable Development expense for the first calendar quarter of 2000.
4.6 Barr will be responsible for all costs associated with the
Research Program, except as expressly provided in this Section 4.
5. Royalty Payments.
5.1 As consideration for the funding provided to Barr by DuPont
under Section 4 hereinabove, Barr shall pay DuPont a royalty equal to ***
in the Territory of each Funded Product. Barr's obligation to
pay DuPont the royalty shall commence sequentially at the time of First
Commercial Sale of each Funded Product and shall sequentially cease upon the
tenth anniversary of the First Commercial Sale of each respective Funded
Product. Barr will pay such royalty to DuPont within thirty (30) days of the end
of each calendar quarter.
-7-
<PAGE> 9
5.2 If Barr launches a generic version of a Funded Product, then
Barr shall pay DuPont a royalty equal to ***
in the Territory. This royalty will be in addition to the royalty owed on each
Funded Product as set forth in Section 5.1. Barr's obligation to pay DuPont the
royalty shall commence at the time of First Commercial Sale of such generic
version and shall be subject to the same terms set forth in Section 5.1
hereinabove.
5.3 Notwithstanding Section 5.1, Barr has the right but not the
obligation to pay DuPont the amount previously paid by DuPont to fund Barr's
development activities for such particular Funded Product, subject to compliance
with applicable laws. Barr may exercise this right by written notice to DuPont
at any time up to one (1) year after Agency Approval of such Funded Product. The
payment by Barr to DuPont shall be paid within thirty (30) days of notice.
5.4 In the event Barr exercises the right given in Section 5.3
hereinabove, then DuPont, up to one (1) year after Agency Approval of the Funded
Product or within sixty (60) days after Barr exercises said right, whichever is
later, may, upon written notice, require Barr to pay DuPont an additional
*** . The payment by Barr to DuPont shall be paid
within thirty (30) days of notice.
5.5 The royalty on a particular Funded Product shall be ***
once Barr makes the payment described in 5.3 for that Funded
Product. The royalty on this same Funded Product shall be *** once
Barr pays DuPont the amount due upon DuPont's exercise of its option described
in 5.4.
5.6 The Parties agree to work out an alternative arrangement of
comparable value and payment pattern acceptable to DuPont to the extent
necessary to comply with statutes, laws, codes or government regulations in a
particular country which restrict or prevent the payment of such royalties by
Barr.
5.7 For up to twelve (12) months following the date of each Sales
Year royalty payment, Barr may recalculate the royalty due for such Sales Year
as a result of any adjustments due to Net Sales for such Sales Year of which
Barr becomes aware or for which Barr becomes entitled. If, as a result of such
recalculation, (i) Barr has overpaid the royalty due DuPont relating to such
Sales Year, Barr shall credit such amount against DuPont's next due royalty; or
(ii) Barr has underpaid the royalty due DuPont relating to such Sales Year, Barr
shall pay such amount to DuPont with its next due royalty, or if no further
royalties are then due to DuPont, Barr shall pay such underpaid amount within
thirty (30) days of the request therefor.
6. Reports, Records.
6.1 Within sixty (60) days of the end of the first calendar
quarter and thirty (30) days of the end of each calendar quarter thereafter
following First Commercial Sale, Barr shall furnish to DuPont a mutually agreed
to written report which shall include the sales by dosage of tablet sold and by
country, the unit volume, gross sales and the Net Sales (including a listing of
all
-8-
<PAGE> 10
deductions set forth in Section 1.12(i)-(vi)) of all Product sold by Barr during
the preceding quarter and the royalties which shall have accrued hereunder. If
no royalties are due to DuPont for any reporting period, the written report
shall so state. DuPont's receipt of any statement or royalty payment shall not
bind it to the accuracy of the statement or payment, regardless of any statement
to the contrary in such statement.
6.2 (a) Barr agrees to keep full and accurate books of
account, records, data and memoranda regarding the sales of the Product in
sufficient detail to enable the royalty payments due to DuPont hereunder to be
determined. Upon no less than ten business days' notice, pursuant to the written
request of DuPont and not more than once in each Sales Year, Barr shall permit
an independent certified public accounting firm of nationally recognized
standing selected by DuPont and reasonably acceptable to Barr, at DuPont's
expense and upon execution of a confidentiality agreement with Barr, to have
access during normal business hours to such records of Barr as may be reasonably
necessary to verify the accuracy of the development royalty. Such examination
shall be conducted during normal business hours in such manner as to not unduly
interfere with Barr's business. These rights with respect to any Sales Year
shall terminate two (2) years after the end of any such Sales Year. The
independent accounting firm shall not share with DuPont any underlying data or
data summaries. The workpapers and other material created by the independent
accountants during the audit will not be made available to DuPont and all Barr's
documents used in the examination will be returned upon completion of the
examination. The report to DuPont shall only state whether the development
royalty is correct or whether and to what extent an underpayment or overpayment
was made. DuPont shall provide Barr the accounting firm's written report within
thirty (30) days of completion of such report.
(b) If such accounting firm correctly concludes that an
overcharge or undercharge was made, then the owing party shall pay the amount
due plus interest at 1.5% per month from the date such amount was originally
paid by Barr, within thirty (30) days of the day DuPont delivers to Barr such
accounting firm's written report so correctly concluding. DuPont shall bear the
full cost of such audit unless such audit correctly discloses that the
overcharge by Barr for the Sales Year differs by more than the greater of
fifteen thousand United States dollars ($15,000) or five percent (5%) from the
amount the accounting firm determines is correct, in such case Barr shall pay
the reasonable fees and expenses charged by the accounting firm. If Barr
disputes the conclusion of the accounting firm, then the parties will resolve
the dispute in accordance with Section 10.12 hereof.
(c) DuPont shall treat all financial information, subject
to review under this Section in accordance with the confidentiality provisions
of this Agreement, and shall cause its accounting firm to enter into a
confidentiality agreement with Barr obligating it to treat all such financial
information in confidence pursuant to such confidentiality agreement. DuPont and
its representatives shall not disclose to any other person, firm, or corporation
any information acquired as a result of any such examination, provided, however,
that nothing contained herein shall be construed to prevent DuPont and/or its
duly authorized representatives from testifying in any court or tribunal of
competent jurisdiction with respect to the information obtained as a result
-9-
<PAGE> 11
of such examination in any action instituted to enforce DuPont 's rights under
the terms of this Agreement.
6.3 (a) Upon no less than ten business days' notice, pursuant
to the written request of DuPont and not more than once in each Sales Year, Barr
shall permit an independent certified public accounting firm of nationally
recognized standing selected by DuPont and reasonably acceptable to Barr, at
DuPont's expense and upon execution of a confidentiality agreement with Barr, to
have access during normal business hours to such records of Barr as may be
reasonably necessary to verify the accuracy and appropriateness of the
Development Costs. Such examination shall be conducted during normal business
hours in such manner as to not unduly interfere with Barr's business. These
rights with respect to any Sales Year shall terminate two (2) years after the
end of any such Sales Year. The independent accounting firm shall not share with
DuPont any underlying data summaries. The workpapers and other material created
by the independent accountants during the audit will not be made available to
DuPont and all Barr's documents used in the examination will be returned upon
completion of the examination. The report to DuPont shall only state whether the
development royalty is correct or whether and to what extent an underpayment or
overpayment was made. DuPont shall provide Barr the accounting firm's written
report within thirty (30) days of completion of such report.
(b) If such accounting firm correctly concludes that an
overcharge or undercharge was made, then the owing party shall pay the amount
due plus interest at 1.5% per month from the date such amount was originally
paid to Barr, within thirty (30) days of the day Barr delivers to DuPont such
accounting firm's written report so correctly concluding. DuPont shall bear the
full cost of such audit unless such audit correctly discloses that the
overcharge by Barr for the audited period differs by more than the greater of
fifteen thousand United States dollars ($15,000) or five percent (5%) from the
amount the accounting firm determines is correct, in such case Barr shall pay
the reasonable fees and expenses charged by the accounting firm. If Barr
disputes the conclusion of the accounting firm, then the parties will resolve
the dispute in accordance with Section 10.12 hereof.
(c) DuPont shall treat all financial information, subject
to review under this Section in accordance with the confidentiality provisions
of this Agreement, and shall cause its accounting firm to enter into a
confidentiality agreement with Barr obligating it to treat all such financial
information in confidence pursuant to such confidentiality agreement. DuPont and
its representatives shall not disclose to any other person, firm, or corporation
any information acquired as a result of any such examination, provided, however,
that nothing contained herein shall be construed to prevent DuPont and/or its
duly authorized representatives from testifying in any court or tribunal of
competent jurisdiction with respect to the information obtained as a result of
such examination in any action instituted to enforce DuPont 's rights under the
terms of this Agreement.
-10-
<PAGE> 12
7. Term, Termination.
7.1 This Agreement is in force as of the Effective Date and shall
remain in force until payment of the last royalty due from Barr to DuPont under
Section 5.
7.2 Either Party may terminate this Agreement (so long as such
Party shall not have materially breached this Agreement and such breach shall
not have been cured) in the event of material breach by the other Party, if the
breaching Party fails to cure the breach within ninety (90) days of receiving
notice of the breach from the non-breaching Party. Upon such cure, this
Agreement shall be deemed to be not terminated and to be in full force.
7.3 Either Party shall have the right to terminate this Agreement
effective immediately in the event the other Party files a voluntary petition in
bankruptcy, is adjudicated as bankrupt, makes a general assignment for the
benefit of creditors, admits in writing that it is insolvent or fails to
discharge within fifteen (15) days an involuntary petition in bankruptcy filed
against it.
7.4 The expiration or termination of this Agreement shall not
relieve the Parties of any obligation accruing prior to such expiration or
termination. The representations and warranties contained in this Agreement as
well as those rights and obligations contained in the terms of this Agreement,
which by their intent or meaning have validity beyond the term of this
Agreement, shall survive the termination or expiration of this Agreement. The
provisions of Sections 2.6, 2.7, 8, 9 and 10 shall survive the expiration or
termination of this Agreement. Any rights and obligations which have accrued
prior to termination or expiration of this Agreement in any respect shall
survive such termination or expiration.
8. Confidential Information.
8.1 As used herein, the term Confidential Information means
information which relates to a Funded Product or its development, manufacture,
testing, Agency Approval, pricing, marketing, sale or support and which is
disclosed by one Party hereto to the other, including, but not limited to,
technical and business information, samples of compounds, the structure or
chemical identity of compounds, the properties and utilities of compounds,
manufacturing procedures, manufacturing processes, manufacturing equipment,
plant layouts, product volumes, quality control procedures, and quality control
standards.
8.2 Each Party shall retain Confidential Information of the other
Party in strict confidence and shall not, directly or indirectly, publish or
disclose it to any Third Party, or use Confidential Information for any purpose
other than the purposes of this Agreement without the prior written consent of
the disclosing Party. Each Party agrees it shall not communicate Confidential
Information of the other Party except to its employees, advisors,
representatives and contractors who have a need to know it. Each Party shall
ensure that any employees, advisors, representatives or contractors who are
placed in a position to learn Confidential Information will have been previously
made aware of the terms of this Agreement, have employment agreements
-11-
<PAGE> 13
or other agreements obligating them to keep such information confidential
consistent with the terms of this Agreement and each Party shall indemnify the
other Party against the misuse of such Confidential Information by its
employees, advisors, representatives or contractors.
8.3 The obligations of confidentiality and nondisclosure shall not
apply to Confidential Information which:
a. at the time of disclosure is in the public domain;
b. after disclosure becomes part of the public domain
through no act or omission by the receiving Party;
c. as shown by written records or other competent proof
was in the possession of the receiving Party prior to disclosure or development
under this Agreement;
d. is rightly received by the receiving Party, without
obligation of secrecy, from a Third Party who was entitled to receive and
transfer such;
e. as shown by written records or other competent proof
is independently developed by employees of the receiving Party who did not have
access to Confidential Information; or
f. a Party hereto is compelled to disclose by a court or
other tribunal of competent jurisdiction. In this case, the compelled Party
shall give the disclosing Party prompt notice so that the disclosing Party can
seek a protective order, and shall exercise reasonable efforts to ensure that
the information is accorded confidential treatment by the court or other
tribunal.
8.4 Termination of this Agreement or any other agreement between
Barr and DuPont shall not affect the secrecy and restrictions on use obligations
under Section 8.2 hereof which shall survive indefinitely. Upon termination of
this Agreement, the receiving Party shall return to the disclosing Party or
destroy any Confidential Information in tangible form in its possession, except
that the receiving Party shall not destroy Confidential Information required to
be retained in order to comply with applicable law, rule or regulation.
8.5 The receiving Party shall also be entitled to disclose the
other Party's Confidential Information (i) that is required to be disclosed in
compliance with applicable laws or regulations (including, without limitation,
to comply with Securities and Exchange Commission, in accordance with Generally
Accepted Accounting Principles, or stock exchange disclosure requirements) or by
order of any governmental body or a court of competent jurisdiction; (ii) as may
be necessary or appropriate in connection with the enforcement of this
Agreement; (iii) as required in furtherance of a Party's obligations under this
Agreement; (iv) as may be necessary to Third Parties in connection with business
transactions with the Parties, provided, that such Third Parties shall be bound
by a confidentiality agreement obligating them to keep such information
-12-
<PAGE> 14
confidential consistent with the terms of this Agreement; (v) as may be required
otherwise provided that a Party give the other Party an outline of the material
to be disclosed and such other Party shall consent to such disclosure; and (vi)
as may be necessary for the conduct of clinical studies; provided, that the
Party required to disclose such information shall use Commercially Reasonable
Efforts to obtain confidential treatment of such information by the agency or
court or other disclosee to the maximum permitted extent under law, and that, in
the case of disclosures under (i) shall provide the other Party with a copy of
the proposed disclosure in sufficient time to allow reasonable opportunity to
comment thereon.
8.6 Each Party shall be entitled, in addition to any other right
or remedy it may have, at law or in equity, to an injunction, without the
posting of any bond or other security, enjoining or restraining any other Party
from any violation or threatened violation of this Section.
8.7 This Agreement shall supersede the Confidential Disclosure
Agreement dated November 16, 1999 between Barr and DuPont and such Confidential
Disclosure Agreement shall be terminated upon the Effective Date of this
Agreement. Each Parties' obligations of confidentiality and nonuse of
information under such Confidential Disclosure Agreement shall continue with
respect to confidential information disclosed prior to its termination.
9. Indemnification.
9.1 Barr shall indemnify and hold harmless DuPont, it officers,
agents, parent companies, advisors , employees and permitted assigns, from and
against any and all loss, claim, injury, damage, cost, or expense, including
reasonable attorneys' fees and expenses of litigation ("Claims"), paid or
payable to a person other than DuPont or its Affiliates in connection with any
illness or personal injury, including death, or property damage relating to the
Funded Products, which results solely from the negligence or willful misconduct
of Barr or from breach of the representations, warranties or obligations of Barr
under this Agreement by Barr or from any Claims under any theory of strict
liability or product liability or from any Claims that DuPont's activities under
this Agreement violate a Third Party's intellectual property rights, except to
the extent that such Claim arises out of or results from the negligence or
misconduct of DuPont or the party seeking to be indemnified, provided, however,
that in no event shall Barr be liable for any consequential, special,
incidental, punitive or multiple damages.
9.2 DuPont shall indemnify and hold harmless Barr, its officers,
agents, parent companies, advisors, employees, and permitted assigns, from and
against any and all Claims paid or payable to a person other than Barr or its
Affiliates relating to the Funded Products, which result solely from the
negligence or willful misconduct of DuPont or from a breach of any
representation, warranty or obligations of DuPont under this Agreement, except
to the extent that such Claim arises out of or results from the negligence or
misconduct of Barr or the party seeking to be indemnified provided, however,
that in no event shall DuPont be liable for any consequential, special,
incidental, punitive or multiple damages.
-13-
<PAGE> 15
9.3 In the event that the negligence or willful misconduct or
breach of this Agreement of both Barr and DuPont contribute to any such Claim,
Barr and DuPont will each indemnify and hold harmless the other with respect to
that portion of the loss, claim, injury, damage, cost, or expense attributable
to its negligence or willful misconduct.
9.4 A condition of the indemnification obligations in this Section
is that, whenever a person or entity entitled to indemnity under this Section
(an "Indemnified Group") has information from which it may reasonably conclude
an incident has occurred which could give rise to a Claim, such indemnified
person or entity shall immediately give notice to the indemnifying Party of all
pertinent data surrounding such incident and, in the event a Claim is made, all
members of the Indemnified Group shall assist the indemnifying Party and
cooperate in the gathering of information with respect to the time, place and
circumstances and in obtaining the names and addresses of any injured Parties
and available witnesses, as well as complete access to all relevant records. No
member of the Indemnified Group shall make any payment or incur any expense in
connection with any such Claim without prior written consent of the indemnifying
Party, provided, however, that an indemnitee may take any reasonably appropriate
action that is necessary to preserve or avoid prejudice to its interests after
the indemnifying Party has been notified of the Claim if the indemnitor states
that it does not believe that the indemnification obligations described herein
apply to such Claim or if the indemnitor does not or cannot perform its
indemnity obligations hereunder. The indemnifying Party shall have the right,
but not the obligation, to control any such action. The obligations set forth in
this Section 9 shall survive the expiration or termination of this Agreement.
10. General Terms & Conditions.
10.1 Representations and Warranties.
Each Party hereby represents and warrants to the other Party as
follows:
a. Such Party is (i) a corporation or general
partnership, as the case may be, duly organized, validly existing and in good
standing under the laws of the state in which it is organized, (ii) has the
corporate or partnership power and authority and the legal right to own and
operate its property and assets, to lease the property and assets it operates
under lease, and to carry on its business as it is now being conducted, and
(iii) is in compliance with all requirements of applicable law, except to the
extent that any noncompliance would not have a material adverse effect on such
Party's ability to perform its obligations under this Agreement.
b. Such Party (i) has the corporate or partnership power
and authority and the legal right to enter into this Agreement and to perform
its obligations hereunder, and (ii) has taken all necessary corporate or
partnership action on its part to authorize the execution and delivery of this
Agreement and the performance of its obligations hereunder. This Agreement has
been duly executed and delivered on behalf of such Party, and constitutes a
legal, valid, binding obligation, enforceable against such Party in accordance
with its terms.
-14-
<PAGE> 16
c. All necessary consents, approvals and authorizations
of all governmental authorities and other persons required to be obtained by
such Party in connection with the execution, delivery and performance of this
Agreement have been and shall be obtained to the extent possible.
d. Notwithstanding anything to the contrary in this
Agreement, the execution and delivery of this Agreement and the performance of
such Party's obligations hereunder (i) do not conflict with or violate any
requirement of applicable laws or regulations or any of the terms of its
certificate of incorporation or by-laws or partnership agreement and (ii) do not
and shall not conflict with, violate or breach or constitute a default or
require any consent under any contractual obligation of such Party.
e. Nothing in this agreement shall be construed as a
representation made, or warranty given, by Barr (i) that any patent will issue
based upon any pending patent application within the Patent Rights, (ii) that
any Patent within the Patent Rights which issues will be valid, or (iii) that
the use of any license granted hereunder or the use of any Patent Rights will
not infringe the Patent or Proprietary Rights of any Third Party. Furthermore,
Barr makes no representation or warranty, express or implied, with respect to
the Patent Rights. Barr specifically disclaims that the Research Program will be
successful, in whole or in part, or that any clinical or other studies
undertaken by it will be successful. Barr does not warrant that its efforts to
research, develop or commercialize any Funded Product will result in regulatory
approval of such Funded Product, nor does Barr warrant that any such Funded
Product will achieve any level of Net Sales or be continued if it obtains
regulatory approval. Except as otherwise expressly stated herein, each Party
hereby disclaims any warranty, express or implied, as to any Funded Product sold
or placed in commerce by or on behalf of Barr or its Affiliates.
f. Nothing in this agreement shall be construed as a
representation or a warranty that Barr has any rights in or to the product known
as ***, nor that Barr will ever obtain any rights to ***.
10.2 Applicable Law/Jurisdiction.
This Agreement is acknowledged to have been made in and shall
be construed, governed, interpreted and applied in accordance with the laws of
the State of Delaware, without giving effect to its conflict of laws provisions;
any disputes under this Agreement shall be subject to the exclusive jurisdiction
and venue of the New York state courts and the Federal courts located in New
York, and the Parties hereby consent to the personal and exclusive jurisdiction
and venue of these courts. Each party hereby waives its rights to a jury trial
for all disputes hereunder.
-15-
<PAGE> 17
10.3 No Waiver.
The failure of either Party to assert a right hereunder or to
insist upon compliance with any term or condition of this Agreement shall not
constitute a waiver of that right or excuse a similar subsequent failure to
perform any such term or condition by the other Party.
10.4 Assignment.
Except as expressly provided herein, neither Party may assign
any of its rights or delegate any of its duties pursuant to this Agreement
without the prior written consent of the other Party, except (but subject to the
prior written consent of the other Party, which consent shall not be
unreasonably withheld) to affiliates and parent companies and to any Third Party
that assumes ownership or control of all or substantially all of the assigning
Party's business; provided that such assignment shall not release the assignor
of its obligations and liabilities hereunder.
10.5 Severability.
If any provision of this Agreement is held to be invalid or
unenforceable, all other provisions will continue in full force and effect, and
the Parties will substitute for the invalid or unenforceable provision a valid
and enforceable provision which conforms as nearly as possible with the original
intent of the Parties.
10.6 Force Majeure.
Neither Party will be charged with any liability for delay in
performance of an obligation under this Agreement (other than payment of amounts
invoiced) when due to a cause beyond the reasonable control of the affected
Party, such as an act of God, war, riots, labor disturbances, fire, explosion,
and compliance in good faith with any governmental law, regulation or order. The
Party affected will give written notice to the other Party of any material delay
due to such causes and shall use all Commercially Reasonable Efforts to minimize
the loss or inconvenience suffered by both Parties. Both Parties shall cooperate
in good faith in order to minimize such loss and inconvenience and to reach an
agreement as to how to proceed.
10.7 No License.
No right or license under any patent or other proprietary
right is granted by either Party under this Agreement, except as specifically
and expressly set forth herein.
10.8 Use of Names.
Both Parties agree not to use or refer to, without the other
Party's prior written permission, the name of the other Party or any of its
affiliates or parent corporations in any public statements, whether oral or
written, unless such disclosures are required by law or regulation.
-16-
<PAGE> 18
10.9 Independent Contractor.
Nothing contained in this Agreement shall be deemed to
constitute a partnership or joint venture between DuPont and Barr, or to
constitute one as the agent of the other. Both Parties shall act solely as
independent contractors, and nothing in this Agreement shall be construed to
give either Party the power or authority, express or implied, to act for, bind,
or commit the other Party.
10.10 Entire Agreement.
The Parties acknowledge that this Agreement sets forth the
entire Agreement and understanding, commitment and undertaking (oral or written)
of the Parties as to the subject matter hereof. This Agreement may be amended
only by a written document signed by authorized representatives of both Parties.
No Party shall have the right to offset or reduce any amount payable under this
Agreement as a result of any other agreement between the Parties hereto or their
affiliates.
10.11 Notices.
Any payment, notice or other communication pursuant to this
Agreement shall be sufficiently made or given on the date of mailing if sent to
such Party by facsimile on such date, with paper copy being sent by first class
mail, postage prepaid, or by next day express delivery service, addressed to it
at its address below (or such address as it shall designate by written notice
given to the other Party).
In the case of DuPont:
Attention: Chief Operating Officer
DuPont Pharmaceuticals Company
974 Centre Road
Wilmington, Delaware 19805
(Fax number: 302-892-7642)
with copy to:
Attention: General Counsel
DuPont Pharmaceuticals Company
974 Centre Road
Wilmington, Delaware 19805
(Fax number: 302-992-4878)
-17-
<PAGE> 19
In the case of Barr:
Barr Laboratories, Inc.
2 Quaker Road
P.O. Box 2900
Pomona, New York 10970
Attention: President
(Fax number: 914-353-8419)
with a copy to:
Barr Laboratories, Inc.
2 Quaker Road
P.O. Box 2900
Pomona, New York 10970
Attention: General Counsel
(Fax number: 914-353-3476)
10.12 Alternative Dispute Resolution Provision.
a. The Parties recognize that a bona fide dispute as to
certain matters may arise from time to time during the term of this Agreement
which may relate to either Party's rights and/or obligations hereunder. The
Parties agree that they shall use all reasonable efforts to resolve in an
amicable manner, any dispute which may arise.
b. If the Parties are unable to resolve such dispute
within thirty (30) days, either Party may, by notice to the other Party, have
such dispute referred to the respective nominees of the parties designated
below. Such nominees shall attempt to resolve the referred dispute by good faith
negotiations within thirty (30) days after such notice is received. The
designated nominees are the Chief Operating Officer for DuPont and the Chief
Executive Officer for Barr.
c. If the designated nominees are not able to resolve
such dispute within such thirty (30) day period, then the Parties shall select a
mediator to aid them in resolving such dispute through the Center for Public
Resources. If both Parties do not agree to pursue mediation or, pursuant to such
mediation, the Parties do not resolve their dispute, the Parties shall at such
time initiate arbitration under the Commercial Dispute Resolutions Rules of the
American Arbitration Association then in effect, by three arbitrators having
experience in the pharmaceuticals industry, with one arbitrator mutually agreed
to by each of DuPont and Barr, and the third arbitrator selected by such
arbitrators. The arbitration proceedings shall be held in New York, New York.
-18-
<PAGE> 20
d. Notwithstanding the above, the complaining Party
reserves the right to seek injunctive relief or other relief, in court of
competent jurisdiction, if, at its election, the complaining Party believes that
immediate relief is necessary to protect its business interest.
IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be
executed by their duly authorized representatives.
DUPONT PHARMACEUTICALS COMPANY BARR LABORATORIES, INC.
By: By:
------------------------------ ------------------------------
Title: Title:
--------------------------- ---------------------------
Date: Date:
---------------------------- ----------------------------
-19-
<PAGE> 21
ATTACHMENT A
***
***
-20-
<PAGE> 22
***
***.
-21-
<PAGE> 23
EXHIBIT I
MAXIMUM QUARTERLY FEES AND DISBURSEMENTS
(Millions)
Calendar Quarters and Years
<TABLE>
<CAPTION>
- ---------------------------------------------------------------------------------------------------------------------
1st Qtr. 2nd Qtr. 3rd Qtr. 4th Qtr. TOTAL
- ---------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
2000 *** *** *** *** ***
- ---------------------------------------------------------------------------------------------------------------------
2001 *** *** *** *** ***
- ---------------------------------------------------------------------------------------------------------------------
2002 *** *** *** *** ***
- ---------------------------------------------------------------------------------------------------------------------
NOT TO EXCEED IN
ANY EVENT THE
FOLLOWING TOTAL
AMOUNT:
$45.00*
- ---------------------------------------------------------------------------------------------------------------------
</TABLE>
* Notwithstanding the above, the total to be provided by DuPont is limited to
$45 million and *** *** per Funded Product.
189818.9
-22-
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> JUN-30-2000
<PERIOD-START> JUL-01-1999
<PERIOD-END> MAR-31-2000
<EXCHANGE-RATE> 1
<CASH> 97,446
<SECURITIES> 8,111
<RECEIVABLES> 96,767<F1>
<ALLOWANCES> 0
<INVENTORY> 77,682
<CURRENT-ASSETS> 281,764
<PP&E> 95,384<F1>
<DEPRECIATION> 0
<TOTAL-ASSETS> 389,471
<CURRENT-LIABILITIES> 98,837
<BONDS> 28,208
0
0
<COMMON> 231
<OTHER-SE> 261,703
<TOTAL-LIABILITY-AND-EQUITY> 389,471
<SALES> 327,612
<TOTAL-REVENUES> 355,433
<CGS> 236,188
<TOTAL-COSTS> 236,188
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 1,892
<INCOME-PRETAX> 42,509
<INCOME-TAX> 15,955
<INCOME-CONTINUING> 26,554
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 26,554
<EPS-BASIC> 1.16
<EPS-DILUTED> 1.12
<FN>
<F1>Accounts Receivable and PP&E are net
</FN>
</TABLE>
